InterMune, interrupted

Given the mixed clinical data that Esbriet pirfenidone has produced in idiopathic pulmonary fibrosis in the past, investors hadn't priced potential results of last week's Phase III ASCEND data into InterMune Inc. (NASDAQ:ITMN). The positive results sent the stock up $23.84 (171%) to $37.80 on Tuesday.